Physician profile
Mary E Abrams
NPI 1376620849
$7,311.02
in general payments reported to CMS, 2019-2025
23 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,021 · 2022: $1,616 · 2023: $1,551 · 2024: $1,459 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,674.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,640.24 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $865.75 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $745.06 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $677.15 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $545.24 | 2021-2024 | Trulance, Xifaxan, Uceris |
| Regeneron Healthcare Solutions, INC. | $343.60 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $327.70 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $255.35 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $243.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $231.55 | 2022-2025 | Ibsrela |
| Celgene Corporation | $228.50 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $217.54 | 2021-2022 | |
| Redhill Biopharma INC. | $200.34 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $178.28 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $144.74 | 2021-2024 | Dificid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $130.94 | 2022-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $93.51 | 2022-2024 | Linzess |
| Lilly USA, LLC | $88.37 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $64.58 | 2024 | Voquezna |
| Novo Nordisk INC | $29.61 | 2025 | Wegovy, Saxenda |
| Mauna Kea Technologies, INC. | $24.26 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.27 | 2021 | |
| Celltrion USA INC. | $14.10 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.